Biotechnology company Imugene (ASX:IMU) said the first patient was dosed in the intratumoral combination group of phase 1 clinical trial on its oncolytic virotherapy candidate, CD19, according to a Monday filing with the Australian bourse.
The study is part of the company's Oasis trial, which aims to evaluate the safety and efficacy of CD19 in patients with advanced or metastatic solid tumors, the filing said. It will explore the direct administration of CD19 into the tumor, as well as intravenous infusion.
The trial is being conducted at seven US sites, with the potential to open a total of 10 sites to recruit up to 40 patients, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。